GBS and One Health

by May Murra Over the past three decades several novel zoonotic infectious diseases have emerged due to human activities such as changes in ecosystems, land-use, intensification of agriculture, urbanization and international travel and trade. A collaboration involving animal, human and environmental health including wildlife health was needed. This collaboration started Read more…

‘Better quantitative understanding of the trajectories of GBS carriage during pregnancy is essential for the design of informative epidemiological studies.’.

Maternal colonization by Group B Streptococcus (GBS) can lead to severe infection in neonates and has also been associated with prematurity and stillbirth. Bronner P. Gonçalves’s comments on research into maternal Group B Strep colonisation. Bronner P. Gonçalves’s research, recently published in the iScience Journal, ‘Inferring longitudinal patterns of group Read more…

Photo by CDC on Unsplash

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors Read more…